{rfName}
BE

Indexed in

License and use

Icono OpenAccess

Altmetrics

Grant support

This research was funded by F. Hoffmann-La Roche Ltd., Basel, Switzerland.

Analysis of institutional authors

Colomer, RAuthor

Share

Publications
>
Article

BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer

Publicated to:Cancers. 14 (11): 2596- - 2022-06-01 14(11), DOI: 10.3390/cancers14112596

Authors: Dang, Chau; Ewer, Michael S.; Delaloge, Suzette; Ferrero, Jean-Marc; Colomer, Ramon; de la Cruz-Merino, Luis; Werner, Theresa L.; Dadswell, Katherine; Verrill, Mark; Eiger, Daniel; Sarkar, Sriparna; de Haas, Sanne Lysbet; Restuccia, Eleonora; Swain, Sandra M.;

Affiliations

F Hoffmann La Roche Ltd, Oncol Biomarker Dev, CH-4070 Basel, Switzerland - Author
Freeman Rd Hosp, Northern Ctr Canc Care, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England - Author
Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA - Author
Hoffmann La Roche Ltd, Prod Dev Oncol, CH-4070 Basel, Switzerland - Author
Hosp Univ La Princesa, Div Med Oncol, Madrid 28006, Spain - Author
Hosp Univ Virgen Macarena, Dept Clin Oncol, Seville 41009, Spain - Author
Inst Gustave Roussy, Dept Med Oncol, F-94805 Paris, France - Author
MedStar Hlth, Washington, DC 20007 USA - Author
Mem Sloan Kettering Canc Ctr, Dept Med, Breast Med Serv, New York, NY 10065 USA - Author
Roche Prod Ltd, Global Prod Dev, Welwyn Garden City AL7 1TW, Herts, England - Author
Roche Prod Ltd, Welwyn Garden City AL7 1TW, Herts, England - Author
Univ Cote dAzur, Ctr Antoine Lacassagne, Dept Med Oncol, F-06110 Nice, France - Author
Univ Texas MD Anderson Canc Ctr, Dept Cardiol, Houston, TX 77030 USA - Author
Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA - Author
See more

Abstract

BERENICE (NCT02132949) assessed the cardiac safety of the neoadjuvant-adjuvant pertuzumab-trastuzumab-based therapy for high-risk, HER2-positive early breast cancer (EBC). We describe key secondary objectives at final analysis. Eligible patients received dose-dense doxorubicin and cyclophosphamide q2w x 4 -> paclitaxel qw x 12 (Cohort A) or 5-fluorouracil, epirubicin, cyclophosphamide q3w x 4 -> docetaxel q3w x 4 (B) as per physician's choice. Pertuzumab-trastuzumab (q3w) was initiated from the taxane start and continued post-surgery to complete 1 year. Median follow-up: 64.5 months. There were no new cardiac issues and a low incidence of Class III/IV heart failure (Cohort B only: one patient (0.5%) in the adjuvant and treatment-free follow-up (TFFU) periods). Fourteen patients (7.7%) had LVEF declines of >= 10% points from baseline to <50% in Cohort A, as did 20 (10.5%) in B during the adjuvant period (12 (6.2%) in A and 7 (3.6%) in B during TFFU). The five-year event-free survival rates in Cohorts A and B were 90.8% (95% CI: 86.5, 95.2) and 89.2% (84.8, 93.6), respectively. The five-year overall survival rates were 96.1% (95% CI: 93.3, 98.9) and 93.8% (90.3, 97.2), respectively. The final analysis of BERENICE further supports pertuzumab-trastuzumab-based therapies as standard of care for high-risk, HER2-positive EBC.

Keywords

cardiac safetyearly breast cancerneoadjuvantpertuzumabCardiac safetyCombinationEarly breast cancerEfficacyHer2MulticenterNeoadjuvantNeosphereOpen-labelPertuzumabPlus trastuzumabRegimensTrastuzumab

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Cancers due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2022, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Oncology.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 1.58. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Field Citation Ratio (FCR) from Dimensions: 5.91 (source consulted: Dimensions Jun 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-06-28, the following number of citations:

  • WoS: 7
  • Scopus: 14
  • Europe PMC: 7

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-06-28:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 34.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 34 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 6.5.
  • The number of mentions on the social network X (formerly Twitter): 1 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: France; Switzerland; United Kingdom; United States of America.